Donation

African-American female researcher in laboratory
Week in Review
March 26
February and March 2026: What's New in Myeloma? 
attendees of an ASH 2025 presentation
Week in Review
February 12
Dr. Joseph Mikhael's Top 10 Myeloma Abstracts from ASH 2025 
imwg conferences series, week in review blog, part 2
Week in Review
July 3
Top Takeaways from the 2025 IMWG Conference Series: Making Sense of Treatment (Part 2 of 2) 
GMMG-HD7 Interim Analysis
ASCO/EHA
June 28
Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone for Newly-Diagnosed Multiple Myeloma: GMMG-HD7 Interim Analysis
ASCO24 Isatuximab Plus Len/Dex/Bortezomib vs IsaRd in Newly Diagnosed Transplant Ineligible Multiple Myeloma
ASCO/EHA
June 12
Isatuximab Plus Len/Dex/Bortezomib vs IsaRd in Newly Diagnosed Transplant Ineligible Multiple Myeloma
Comparison of Time to Next Treatment or Death between Front-Line Daratumumab, Lenalidomide, and Dexamethasone (DRd) and Bortezomib, Lenalidomide, and Dexamethasone (VRd) in Transplant Ineligible Patients with Multiple Myeloma
ASH
January 11
Comparison of Time to Next Treatment or Death between Front-Line Daratumumab, Lenalidomide, and Dexamethasone (DRd) and Bortezomib, Lenalidomide, and Dexamethasone (VRd) in Transplant Ineligible Patients with Multiple Myeloma
Phase 3 Randomized Study of Daratumumab (DARA) + Bortezomib, Lenalidomide, and Dexamethasone (VRd) Versus Vrd Alone in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Who Are Eligible for Autologous Stem Cell Transplantation (ASCT): Primary Results of the Perseus Trial
ASH
January 8
Phase 3 Randomized Study of Daratumumab (DARA) + Bortezomib, Lenalidomide, and Dexamethasone (VRd) Versus Vrd Alone in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Who Are Eligible for ASCT: Primary Results of the Perseus Trial
Dr. Romano on the effects of Arginine Deprivation in Multiple Myeloma
ASH
December 15
Effects of Arginine Deprivation to Proteasome Inhibitor Resistance in Multiple Myeloma
EHA 2021 Iberdomide with Dex and Daratumumab, Bortezomib, and Carfilzomib in relapsed refractory multiple myeloma
ASCO/EHA
July 9
Iberdomide in Combination with Dexamethasone and Daratumumab, Bortezomib, or Carfilzomib In Patients with Relapsed Refractory Multiple Myeloma
ASCO 2021 Optiumum MUKnine study
ASCO/EHA
June 9
Depth of response and minimal residual disease status in ultra high-risk multiple myeloma and plasma cell leukemia treated with DARA-CVRd: Results of the UK optimum/MUKnine trial
Carfilzomib twice weekly with KdD vs DVd Dr. Katja Weisel ASH 2020
ASH
December 11
Carfilzomib Twice Weekly in Combination with Dex and Daratumumab Vs Dara with Bortezomib and Dex
a group of medical researchers circle up around an ipad in a lobby
Week in Review
March 15
IMF Launches New Education Initiative
Subscribe to bortezomib

Give Where Most Needed

Learn More